Strengths and limitations of new artificial intelligence tool for rare disease epidemiology by David Lapidus

Get full text

An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion by Ryan Colburn, David Lapidus

Get full text

Correction: Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019 by Sarah J. Howe, David Lapidus, Michael Hull, Jason Yeaw, Tanya Stevenson, Jacinda B. Sampson

Get full text

Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization by Robert J. Pignolo, Edward C. Hsiao, Genevieve Baujat, David Lapidus, Adam Sherman, Frederick S. Kaplan

Get full text

Prevalence, characteristics, and costs of diagnosed homocystinuria, elevated homocysteine, and phenylketonuria in the United States: a retrospective claims-based comparison by Marcia Sellos-Moura, Frank Glavin, David Lapidus, Kristin Evans, Carolyn R. Lew, Debra E. Irwin

Get full text

Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases by Geneviève Baujat, Rémy Choquet, Stéphane Bouée, Viviane Jeanbat, Laurène Courouve, Amélie Ruel, Caroline Michot, Kim-Hanh Le Quan Sang, David Lapidus, Claude Messiaen, Paul Landais, Valérie Cormier-Daire

Get full text